Patent Cliff Calendar
Drugs losing US patent exclusivity in 2027
164 drugs face loss of exclusivity in 2027 · 146 small-molecule via Orange Book · 18 biologic via Purple Book BPCIA
What "patent cliff" means
When a drug's primary US patent expires, generic (small molecule) or biosimilar (biologic) competitors can apply to sell copies of that drug. The originator's revenue typically erodes by 30-50% within the first year of generic entry, and 60-80% within three years. For biologics, BPCIA 12-year reference product exclusivity acts as a parallel runway alongside patent protection.
2027 is a near-term cliff (1 year away). Biosimilar / generic filers are preparing IPR petitions and 351(k) / ANDA filings now.
Drugs losing exclusivity in 2027
| Drug | Manufacturer | Type | Earliest expiry | Patent estate | Patent classifications |
|---|---|---|---|---|---|
| Kalydeco (IVACAFTOR) | Vertex Pharms Inc | Small molecule | 2027-01-06 | 114 patents | Composition of Matter Method of Use Other |
| Imbruvica (ibrutinib) | AbbVie | Small molecule | 2027-04-26 | 87 patents | Composition of Matter Method of Use Other |
| Duragesic (fentanyl) | Johnson & Johnson (Janssen Pharmaceutica) | Small molecule | 2027-01-25 | 54 patents | Formulation Method of Use |
| Jardiance (empagliflozin) | Boehringer Ingelheim | Small molecule | 2027-04-15 | 44 patents | Composition of Matter Formulation Method of Use Other |
| cysteamine-bitartrate (CYSTEAMINE BITARTRATE) | — | Small molecule | 2027-01-26 | 44 patents | Method of Use Other |
| Topamax (topiramate) | Janssen | Small molecule | 2027-11-16 | 36 patents | Method of Use |
| chembl-chembl2103744 (MORPHINE SULFATE) | — | Small molecule | 2027-06-19 | 36 patents | Formulation Method of Use |
| oxcarbazepine (OXCARBAZEPINE) | — | Small molecule | 2027-04-13 | 33 patents | Formulation Method of Use |
| Farxiga (DAPAGLIFLOZIN) | AstraZeneca | Small molecule | 2027-02-18 | 30 patents | Method of Use Other |
| Subutex (Buprenorphine Hydrochloride) | Indivior | Small molecule | 2027-07-23 | 26 patents | Method of Use |
| nicardipine-hydrochloride (NICARDIPINE HYDROCHLORIDE) | — | Small molecule | 2027-04-18 | 22 patents | Formulation Method of Use |
| Abilify (aripiprazole) | Generic (originally Otsuka/BMS) | Small molecule | 2027-03-02 | 21 patents | Method of Use |
| Injectafer (FERRIC CARBOXYMALTOSE) | Am Regent | Small molecule | 2027-01-08 | 20 patents | Composition of Matter Method of Use |
| Invokana (CANAGLIFLOZIN) | Johnson & Johnson | Small molecule | 2027-07-14 | 20 patents | Composition of Matter Method of Use |
| Tradjenta (LINAGLIPTIN) | Boehringer Ingelheim | Small molecule | 2027-05-04 | 19 patents | Formulation Method of Use Other |
| minocycline-hydrochloride (MINOCYCLINE HYDROCHLORIDE) | — | Small molecule | 2027-03-07 | 19 patents | Formulation Method of Use |
| doxepin-hydrochloride (DOXEPIN HYDROCHLORIDE) | — | Small molecule | 2027-05-18 | 18 patents | Method of Use |
| Jesduvroq (DAPRODUSTAT) | GSK | Small molecule | 2027-06-22 | 15 patents | Method of Use |
| Risperdal (risperidone) | Johnson & Johnson (Janssen) | Small molecule | 2027-11-12 | 14 patents | Method of Use |
| oxymorphone-hydrochloride (OXYMORPHONE HYDROCHLORIDE) | — | Small molecule | 2027-06-21 | 14 patents | Method of Use |
| sufentanil-citrate (SUFENTANIL CITRATE) | — | Small molecule | 2027-01-05 | 13 patents | Formulation Method of Use |
| Arthrotec (Diclofenac Sodium) | Pfizer | Small molecule | 2027-03-22 | 12 patents | Formulation Method of Use |
| Palbociclib (palbociclib) | Pfizer Inc. | Small molecule | 2027-03-05 | 12 patents | Composition of Matter Other |
| Toviaz (Fesoterodine Fumarate) | Pfizer | Small molecule | 2027-06-07 | 12 patents | Formulation Method of Use Other |
| difelikefalin-acetate (DIFELIKEFALIN ACETATE) | — | Small molecule | 2027-11-12 | 12 patents | Method of Use |
| vadadustat (VADADUSTAT) | — | Small molecule | 2027-06-26 | 12 patents | Composition of Matter Method of Use |
| nilotinib-hydrochloride (Nilotinib Hydrochloride) | Jan Beumer | Small molecule | 2027-01-18 | 12 patents | Formulation Other |
| Dificid (FIDAXOMICIN) | Cubist Pharms Llc | Small molecule | 2027-03-04 | 10 patents | Composition of Matter Formulation Method of Use Other |
| Lyrica (Pregabalin) | Pfizer Inc. | Small molecule | 2027-05-02 | 9 patents | Other |
| Uptravi (SELEXIPAG) | AstraZeneca | Small molecule | 2027-04-30 | 9 patents | Other |
| Arnuity Ellipta (FLUTICASONE FUROATE) | Haleon Us Holdings | Small molecule | 2027-06-14 | 8 patents | Composition of Matter Method of Use Other |
| Ozempic (semaglutide) | Novo Nordisk | Small molecule | 2027-02-27 | 8 patents | Formulation |
| Tybost (COBICISTAT) | Gilead Sciences | Small molecule | 2027-02-27 | 8 patents | Other |
| Fanapt (ILOPERIDONE) | Vanda Pharms Inc | Small molecule | 2027-11-02 | 7 patents | Method of Use |
| Lynparza (olaparib) | AstraZeneca | Small molecule | 2027-08-12 | 7 patents | Composition of Matter Method of Use |
| Prezista (DARUNAVIR) | Janssen Prods | Small molecule | 2027-06-26 | 7 patents | Other |
| Subutex (BUPRENORPHINE) | Purdue Pharma Lp | Small molecule | 2027-01-10 | 7 patents | Method of Use |
| metformin-hydrochloride (METFORMIN HYDROCHLORIDE) | — | Small molecule | 2027-01-22 | 7 patents | Formulation Other |
| lomitapide-mesylate (LOMITAPIDE MESYLATE) | — | Small molecule | 2027-08-19 | 7 patents | Method of Use |
| Amitiza (LUBIPROSTONE) | Sucampo Pharma Llc | Small molecule | 2027-01-23 | 6 patents | Formulation |
| Erleada (apalutamide) | Johnson & Johnson | Small molecule | 2027-03-27 | 6 patents | Composition of Matter Formulation Method of Use |
| Keppra (levetiracetam) | Generic (originally UCB Pharma) | Small molecule | 2027-09-03 | 6 patents | Formulation |
| Kyprolis (carfilzomib) | Amgen | Small molecule | 2027-01-20 | 6 patents | Formulation Other |
| Neupro (ROTIGOTINE) | UCB | Small molecule | 2027-09-01 | 6 patents | Method of Use |
| Remodulin (TREPROSTINIL) | United Therap | Small molecule | 2027-05-14 | 6 patents | Method of Use |
| Revlimid (lenalidomide) | Bristol-Myers Squibb | Small molecule | 2027-04-27 | 6 patents | Composition of Matter |
| Vitekta (ELVITEGRAVIR) | Gilead Sciences | Small molecule | 2027-02-27 | 6 patents | Other |
| naloxone-hydrochloride (Naloxone Hydrochloride) | Pfizer Inc. | Small molecule | 2027-02-20 | 6 patents | Formulation Method of Use |
| pexidartinib-hydrochloride (PEXIDARTINIB HYDROCHLORIDE) | — | Small molecule | 2027-11-21 | 6 patents | Composition of Matter |
| Aveed (TESTOSTERONE UNDECANOATE) | Marius | Small molecule | 2027-01-06 | 5 patents | Formulation Method of Use |
| Cytarabine (Cytarabine) | Nippon Shinyaku Co., Ltd. | Small molecule | 2027-01-23 | 5 patents | Formulation Method of Use Other |
| Opsumit (MACITENTAN) | AstraZeneca | Small molecule | 2027-03-11 | 5 patents | Method of Use Other |
| Xalkori (crizotinib) | Pfizer | Small molecule | 2027-05-12 | 5 patents | Method of Use |
| fentanyl-citrate (FENTANYL CITRATE) | — | Small molecule | 2027-07-23 | 5 patents | Method of Use |
| bosutinib-monohydrate (BOSUTINIB MONOHYDRATE) | — | Small molecule | 2027-05-23 | 5 patents | Other |
| Androgel (TESTOSTERONE) | Besins Hlthcare | Small molecule | 2027-02-26 | 4 patents | Method of Use |
| Dexilant (DEXLANSOPRAZOLE) | Takeda | Small molecule | 2027-02-02 | 4 patents | Other |
| Eliquis (apixaban) | Bristol-Myers Squibb | Small molecule | 2027-05-21 | 4 patents | Other |
| Emend (APREPITANT) | Merck & Co. | Small molecule | 2027-09-26 | 4 patents | Method of Use |
| Eucrisa (Crisaborole) | Anacor Pharms Inc | Small molecule | 2027-02-16 | 4 patents | Method of Use Other |
| Letairis (AMBRISENTAN) | Gilead Sciences | Small molecule | 2027-12-11 | 4 patents | Method of Use |
| Vascepa (ICOSAPENT ETHYL) | Amarin Pharms | Small molecule | 2027-05-31 | 4 patents | Method of Use |
| Zykadia (ceritinib) | Novartis | Small molecule | 2027-11-20 | 4 patents | Composition of Matter Method of Use |
| olodaterol-hydrochloride (OLODATEROL HYDROCHLORIDE) | — | Small molecule | 2027-01-19 | 4 patents | Composition of Matter Formulation Other |
| capmatinib-hydrochloride (CAPMATINIB HYDROCHLORIDE) | — | Small molecule | 2027-11-19 | 4 patents | Composition of Matter Method of Use |
| ponatinib-hydrochloride (PONATINIB HYDROCHLORIDE) | — | Small molecule | 2027-01-24 | 4 patents | Composition of Matter |
| umeclidinium-bromide (UMECLIDINIUM BROMIDE) | — | Small molecule | 2027-06-14 | 4 patents | Composition of Matter Method of Use Other |
| chlorhexidine-gluconate (CHLORHEXIDINE GLUCONATE) | — | Small molecule | 2027-04-25 | 4 patents | Method of Use |
| Azelex (AZELAIC ACID) | Leo Pharma As | Small molecule | 2027-09-18 | 3 patents | Formulation Method of Use |
| Deltasone (prednisone) | Generic (originally Schering) | Small molecule | 2027-08-03 | 3 patents | Method of Use |
| Differin (ADAPALENE) | Galderma Labs Lp | Small molecule | 2027-07-18 | 3 patents | Method of Use |
| Epipen (epinephrine) | Pfizer Inc. | Small molecule | 2027-02-27 | 3 patents | Formulation |
| Linzess (LINACLOTIDE) | AbbVie | Small molecule | 2027-02-28 | 3 patents | Other |
| Pristiq (Desvenlafaxine Succinate) | Pfizer | Small molecule | 2027-07-05 | 3 patents | Composition of Matter |
| Rayaldee (CALCIFEDIOL) | — | Small molecule | 2027-02-02 | 3 patents | Formulation Method of Use |
| Spiriva (TIOTROPIUM BROMIDE) | Boehringer Ingelheim | Small molecule | 2027-03-31 | 3 patents | Formulation Other |
| Xtandi (enzalutamide) | Astellas Pharma | Small molecule | 2027-08-13 | 3 patents | Composition of Matter |
| sitagliptin-phosphate (SITAGLIPTIN PHOSPHATE) | — | Small molecule | 2027-05-24 | 3 patents | Other |
| afatinib-dimaleate (AFATINIB DIMALEATE) | — | Small molecule | 2027-05-09 | 3 patents | Other |
| Amaryl (GLIMEPIRIDE) | Sanofi | Small molecule | 2027-01-30 | 2 patents | Formulation |
| Argatroban (ARGATROBAN) | Hikma Pharm Co Ltd | Small molecule | 2027-09-26 | 2 patents | Method of Use |
| Aubagio (TERIFLUNOMIDE) | Sanofi | Small molecule | 2027-03-12 | 2 patents | Other |
| Catapres-Tts-1 (CLONIDINE) | Lavipharm | Small molecule | 2027-04-17 | 2 patents | Formulation |
| Decadron (dexamethasone) | Generic (originally Merck) | Small molecule | 2027-12-19 | 2 patents | Formulation Method of Use |
| Derma-Smoothe/Fs (FLUOCINOLONE ACETONIDE) | Eurofarma | Small molecule | 2027-08-12 | 2 patents | Formulation |
| Jadelle (LEVONORGESTREL) | Fdn Consumer | Small molecule | 2027-02-07 | 2 patents | Formulation |
| Kybella (DEOXYCHOLIC ACID) | AbbVie | Small molecule | 2027-12-10 | 2 patents | Method of Use |
| Lastacaft (ALCAFTADINE) | AbbVie | Small molecule | 2027-03-19 | 2 patents | Method of Use |
| Lumigan (BIMATOPROST) | — | Small molecule | 2027-04-07 | 2 patents | Composition of Matter Method of Use |
| Nexplanon (ETONOGESTREL) | — | Small molecule | 2027-05-31 | 2 patents | Formulation |
| Nourianz (ISTRADEFYLLINE) | Kyowa Kirin | Small molecule | 2027-09-05 | 2 patents | Formulation |
| Ocaliva (OBETICHOLIC ACID) | Intercept Pharms Inc | Small molecule | 2027-02-21 | 2 patents | Composition of Matter |
| Phoslo (CALCIUM ACETATE) | Fresenius Medcl Care | Small molecule | 2027-07-20 | 2 patents | Method of Use |
| Picato (INGENOL MEBUTATE) | Leo Labs | Small molecule | 2027-07-06 | 2 patents | Formulation |
| Steglatro (ERTUGLIFLOZIN) | Merck & Co. | Small molecule | 2027-05-24 | 2 patents | Other |
| Travatan (TRAVOPROST) | — | Small molecule | 2027-09-20 | 2 patents | Formulation |
| Tukysa (tucatinib) | Seagen | Small molecule | 2027-05-09 | 2 patents | Method of Use |
| Tymlos (ABALOPARATIDE) | Radius | Small molecule | 2027-10-03 | 2 patents | Formulation Method of Use |
| Vibativ (TELAVANCIN HYDROCHLORIDE) | Cumberland | Small molecule | 2027-01-01 | 2 patents | Composition of Matter |
| Victrelis (BOCEPREVIR) | Merck & Co. | Small molecule | 2027-03-17 | 2 patents | Method of Use |
| Vocabria (CABOTEGRAVIR) | GSK | Small molecule | 2027-06-30 | 2 patents | Method of Use |
| Xifaxan (rifaximin) | Bausch Health | Small molecule | 2027-09-02 | 2 patents | Composition of Matter Method of Use |
| Zocor (simvastatin) | Merck & Co. | Small molecule | 2027-04-26 | 2 patents | Formulation |
| Zovirax (ACYCLOVIR) | Ligand Pharms | Small molecule | 2027-03-23 | 2 patents | Method of Use |
| telotristat-etiprate (TELOTRISTAT ETIPRATE) | — | Small molecule | 2027-12-11 | 2 patents | Composition of Matter Method of Use |
| abacavir-sulfate (ABACAVIR SULFATE) | — | Small molecule | 2027-10-05 | 2 patents | Composition of Matter |
| ivabradine-hydrochloride (IVABRADINE HYDROCHLORIDE) | — | Small molecule | 2027-06-12 | 2 patents | Other |
| regadenoson (Regadenoson) | Pfizer Inc. | Small molecule | 2027-02-02 | 2 patents | Composition of Matter Formulation |
| avacincaptad-pegol-sodium (AVACINCAPTAD PEGOL SODIUM) | — | Small molecule | 2027-02-14 | 2 patents | Composition of Matter Method of Use |
| Altabax (RETAPAMULIN) | Almirall | Small molecule | 2027-02-14 | 1 patents | Composition of Matter |
| Amoxil (amoxicillin) | Generic (originally Beecham/GSK) | Small molecule | 2027-05-07 | 1 patents | Method of Use |
| Antizol (FOMEPIZOLE) | Par Pharm Inc | Small molecule | 2027-06-30 | 1 patents | Composition of Matter |
| Asclera (POLIDOCANOL) | Provensis | Small molecule | 2027-11-19 | 1 patents | Method of Use |
| Beleodaq (belinostat) | Acrotech Biopharma | Small molecule | 2027-10-27 | 1 patents | Formulation |
| Camptosar (Irinotecan Hydrochloride) | Pfizer | Small molecule | 2027-01-06 | 1 patents | Composition of Matter |
| Diprolene (BETAMETHASONE DIPROPIONATE) | Merck & Co. | Small molecule | 2027-09-27 | 1 patents | Formulation |
| Duavee (Bazedoxifene Acetate) | Pfizer Inc. | Small molecule | 2027-03-10 | 1 patents | Method of Use |
| Ecclock (SOFPIRONIUM BROMIDE) | Kaken Pharmaceutical | Small molecule | 2027-03-26 | 1 patents | Composition of Matter |
| Elocon (MOMETASONE FUROATE) | Merck & Co. | Small molecule | 2027-06-12 | 1 patents | Method of Use |
| Inomax (NITRIC OXIDE) | Vero Biotech Inc | Small molecule | 2027-04-21 | 1 patents | Formulation |
| Klisyri (TIRBANIBULIN) | Almirall | Small molecule | 2027-12-28 | 1 patents | Formulation |
| Mektovi (binimetinib) | Pfizer | Small molecule | 2027-03-13 | 1 patents | Composition of Matter |
| Nevanac (NEPAFENAC) | Harrow Health | Small molecule | 2027-01-31 | 1 patents | Method of Use |
| Onpattro (PATISIRAN SODIUM) | Alnylam Pharmaceuticals | Small molecule | 2027-10-03 | 1 patents | Formulation |
| Ovide (MALATHION) | Taro | Small molecule | 2027-02-01 | 1 patents | Method of Use |
| Sandimmune (cyclosporine) | Novartis AG (originally Sandoz) | Small molecule | 2027-11-03 | 1 patents | Formulation |
| Tracleer (BOSENTAN) | AstraZeneca | Small molecule | 2027-12-28 | 1 patents | Formulation |
| Triferic (FERRIC PYROPHOSPHATE CITRATE) | Rockwell Medical Inc | Small molecule | 2027-09-08 | 1 patents | Method of Use |
| Tussionex Pennkinetic (CHLORPHENIRAMINE MALEATE) | Bayer | Small molecule | 2027-02-28 | 1 patents | Formulation |
| Verdeso (DESONIDE) | Padagis Us | Small molecule | 2027-08-13 | 1 patents | Method of Use |
| Vibramycin (doxycycline) | Generic (originally Pfizer) | Small molecule | 2027-12-19 | 1 patents | Method of Use |
| Winlevi (CLASCOTERONE) | Sun Pharma | Small molecule | 2027-01-12 | 1 patents | Method of Use |
| Zolinza (VORINOSTAT) | Merck & Co. | Small molecule | 2027-03-11 | 1 patents | Composition of Matter |
| esketamine-hydrochloride (ESKETAMINE HYDROCHLORIDE) | — | Small molecule | 2027-03-20 | 1 patents | Method of Use |
| sorafenib-tosylate (SORAFENIB TOSYLATE) | — | Small molecule | 2027-12-24 | 1 patents | Method of Use |
| macimorelin-acetate (MACIMORELIN ACETATE) | — | Small molecule | 2027-10-12 | 1 patents | Method of Use |
| mesalamine (MESALAMINE) | — | Small molecule | 2027-07-24 | 1 patents | Composition of Matter |
| fingolimod-hydrochloride (FINGOLIMOD HYDROCHLORIDE) | — | Small molecule | 2027-12-25 | 1 patents | Method of Use |
| chembl-chembl428647 (PACLITAXEL) | — | Small molecule | 2027-02-13 | 1 patents | Other |
| chembl-chembl1200962 (CEFEPIME HYDROCHLORIDE) | — | Small molecule | 2027-12-03 | 1 patents | Method of Use |
| chembl-chembl112 (ACETAMINOPHEN) | — | Small molecule | 2027-06-01 | 1 patents | Method of Use |
| fostemsavir-tromethamine (FOSTEMSAVIR TROMETHAMINE) | — | Small molecule | 2027-11-19 | 1 patents | Composition of Matter |
| nusinersen-sodium (NUSINERSEN SODIUM) | — | Small molecule | 2027-07-11 | 1 patents | Composition of Matter |
| uridine-triacetate (URIDINE TRIACETATE) | — | Small molecule | 2027-08-17 | 1 patents | Method of Use |
| albuterol-sulfate (ALBUTEROL SULFATE) | — | Small molecule | 2027-03-31 | 1 patents | Formulation |
| givinostat-hydrochloride (GIVINOSTAT HYDROCHLORIDE) | — | Small molecule | 2027-01-15 | 1 patents | Composition of Matter |
| BASAGLAR KWIKPEN (INSULIN GLARGINE) | Sanofi | Biologic | 2027-12-16 | BPCIA 12-yr exclusivity | BPCIA Biologic Exclusivity |
| COSENTYX (secukinumab) | Novartis | Biologic | 2027-01-21 | BPCIA 12-yr exclusivity | BPCIA Biologic Exclusivity |
| DARZALEX (daratumumab) | Johnson & Johnson | Biologic | 2027-11-16 | BPCIA 12-yr exclusivity | BPCIA Biologic Exclusivity |
| EMPLICITI (elotuzumab) | Bristol-Myers Squibb | Biologic | 2027-11-30 | BPCIA 12-yr exclusivity | BPCIA Biologic Exclusivity |
| HUMALOG KWIKPEN (INSULIN LISPRO) | Eli Lilly | Biologic | 2027-05-26 | BPCIA 12-yr exclusivity | BPCIA Biologic Exclusivity |
| KANUMA | ALEXION PHARM | Biologic | 2027-12-08 | BPCIA 12-yr exclusivity | BPCIA Biologic Exclusivity |
| NUCALA (MEPOLIZUMAB) | GSK | Biologic | 2027-11-04 | BPCIA 12-yr exclusivity | BPCIA Biologic Exclusivity |
| PORTRAZZA (NECITUMUMAB) | Eli Lilly Co | Biologic | 2027-11-24 | BPCIA 12-yr exclusivity | BPCIA Biologic Exclusivity |
| PRALUENT (ALIROCUMAB) | Sanofi | Biologic | 2027-07-24 | BPCIA 12-yr exclusivity | BPCIA Biologic Exclusivity |
| PRAXBIND (IDARUCIZUMAB) | Boehringer Ingelheim | Biologic | 2027-10-16 | BPCIA 12-yr exclusivity | BPCIA Biologic Exclusivity |
| STRENSIQ (ASFOTASE ALFA) | AstraZeneca | Biologic | 2027-10-23 | BPCIA 12-yr exclusivity | BPCIA Biologic Exclusivity |
| TOUJEO (INSULIN GLARGINE) | Sanofi | Biologic | 2027-02-25 | BPCIA 12-yr exclusivity | BPCIA Biologic Exclusivity |
| TRESIBA (INSULIN DEGLUDEC) | Novo Nordisk | Biologic | 2027-09-25 | BPCIA 12-yr exclusivity | BPCIA Biologic Exclusivity |
| UNITUXIN (DINUTUXIMAB) | United Therap | Biologic | 2027-03-10 | BPCIA 12-yr exclusivity | BPCIA Biologic Exclusivity |
| ZARXIO (Filgrastim-sndz) | M.D. Anderson Cancer Center | Biologic | 2027-03-06 | BPCIA 12-yr exclusivity | BPCIA Biologic Exclusivity |
| (unknown) | NPS PHARMS INC | Biologic | 2027-01-23 | BPCIA 12-yr exclusivity | BPCIA Biologic Exclusivity |
| (unknown) | BRISTOL MYERS SQUIBB | Biologic | 2027-03-04 | BPCIA 12-yr exclusivity | BPCIA Biologic Exclusivity |
| (unknown) | NOVO | Biologic | 2027-09-25 | BPCIA 12-yr exclusivity | BPCIA Biologic Exclusivity |
Sources
- FDA Orange Book — patents listed against approved small-molecule drugs (NDAs).
- FDA Purple Book — BPCIA 12-year reference product exclusivity for licensed biologics (BLAs).
- USPTO PatentsView + Google Patents — title, abstract, and claim text grounding.
- Drug Landscape — AI-augmented enrichment and consolidated estate analysis.
Data shown is sourced from public regulatory and patent databases as of 2026-05-17. Patent term extensions, supplementary protection certificates, pediatric exclusivity, and pending IPR challenges may shift the effective expiry date. Not legal advice.